EUVIMEDDescoperă EUVIMED
Übersichtsarbeit

Multifaceted Therapeutic Impacts of Cucurbitacin B: Recent Evidences From Preclinical Studies

Meenal Sahu, Tripti Paliwal, Smita Jain, Kanika Verma, Dipjyoti Chakraborty, Shivangi Jaiswal, Jaya Dwivedi iD, Swapnil Sharma iD

Phytotherapy Research · 2025-05 · 39 (5) · 1966-1995

DOI: 10.1002/ptr.8454 ↗

At a glance

Übersichtsarbeit in Phytotherapy Research, published online on 2025-02-18. Written by Meenal Sahu and 7 co-authors. Institution: Department of Bioscience & Biotechnology, Banasthali Vidyapith, Banasthali, Rajasthan, India. Major MEDLINE topics: Triterpenes. Cited 15 times so far (Crossref); 161 references.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

The most prevalent and bioactive cucurbitacin is Cucurbitacin B (CuB, C 32 H 46 O 8 ), which is a tetracyclic triterpene chiefly present in the Cucurbitaceae family. CuB has a wide spectrum of pharmacological properties namely antioxidant, anticancer, hepatoprotective, anti‐inflammatory, antiviral, hypoglycaemic, insecticidal, and neuroprotective properties, owing to its ability to regulate several signaling pathways, including the Janus kinase/signal transducer and activator of transcription‐3 (JAK/STAT3), AMP‐activated protein kinase (AMPK), nuclear factor (NF)‐κB, nuclear factor erythroid 2‐related factor‐2/antioxidant responsive element (Nrf2/ARE), phosphoinositide 3‐kinase (PI3K)/Akt, mitogen‐activated protein kinase (MAPK), Hippo‐Yes‐associated protein (YAP), focal adhesion kinase (FAK), cancerous inhibitor of protein phosphatase‐2A/protein phosphatase‐2A (CIP2A/PP2A), Wnt and Notch pathways. The present review highlights the medicinal attributes of Cucurbitacin B (CuB) with special emphasis on their signaling pathways to provide key evidence of its therapeutic utility in the near future.

Subjects

MeSH terms (MEDLINE)

TriterpenesHumansAnimalsSignal Transduction

Author keywords

Cucumis callosusCucurbitacin Bpharmacologysignalingtoxicity

Substances

Triterpenescucurbitacin B

Authors and institutions

  • Department of Bioscience & Biotechnology, Banasthali Vidyapith, Banasthali, Rajasthan, India.
  • Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, India.
  • Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Kishangarh, Rajasthan, India.
  • Department of Internal Medicine, Division of Cardiology, LSU Health Sciences Center, Shreveport, Louisiana, USA.
  • Department of Chemistry, Banasthali Vidyapith, Banasthali, Rajasthan, India.

ORCID profiles: Jaya Dwivedi, Swapnil Sharma

Cite

APA

Sahu, M., Paliwal, T., Jain, S., Verma, K., Chakraborty, D., Jaiswal, S., Dwivedi, J., & Sharma, S. (2025). Multifaceted Therapeutic Impacts of Cucurbitacin B: Recent Evidences From Preclinical Studies. Phytotherapy Research, 39(5), 1966-1995. https://doi.org/10.1002/ptr.8454

Vancouver

Sahu M, Paliwal T, Jain S, Verma K, Chakraborty D, Jaiswal S, et al. Multifaceted Therapeutic Impacts of Cucurbitacin B: Recent Evidences From Preclinical Studies. Phytotherapy Research. 2025;39(5):1966-1995. doi:10.1002/ptr.8454

BibTeX
@article{Sahu2025,
  author = {Sahu, Meenal and Paliwal, Tripti and Jain, Smita and Verma, Kanika and Chakraborty, Dipjyoti and Jaiswal, Shivangi and Dwivedi, Jaya and Sharma, Swapnil},
  title = {Multifaceted Therapeutic Impacts of Cucurbitacin B: Recent Evidences From Preclinical Studies},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {5},
  pages = {1966--1995},
  doi = {10.1002/ptr.8454}
}
Start for free →